文献速递甲状腺疾病

分化型甲状腺癌转移性颈部淋巴结的主动监测:一项回顾性单中心队列研究

Active Surveillance of Differentiated Thyroid Cancer Metastatic Cervical Lymph Nodes: A Retrospective Single-Center Cohort Study.
PubMed 文献 · Thyroid · 2023-02-15

该回顾性单中心队列纳入40例经活检证实颈部转移淋巴结≤2.0 cm且主动监测至少6个月的分化型甲状腺癌患者。中位随访27.5个月,14例(35%)出现疾病进展,8例转手术,无永久手术并发症。作者认为多数小转移淋巴结保持稳定并可安全主动监测,但受回顾性设计、小样本和短随访限制,需进一步前瞻性长期研究。

要点

  • 40例分化型甲状腺癌患者中,14例(35%)在主动监测期间出现疾病进展。
  • 进展者中8例转手术,无永久手术并发症报告;继续监测的6例中5例后续无进一步进展。
  • 作者认为多数小转移颈部淋巴结保持稳定并可安全主动监测,但需进一步前瞻性长期研究。

核心结论

  • 作者观察到多数小转移性颈部淋巴结保持稳定,主动监测可安全管理,但受回顾性设计、小样本和短随访限制,需进一步前瞻性长期研究。

研究设计与样本

  • 回顾性单中心队列研究,纳入巴西一家大学附属三级医疗中心经活检证实颈部转移淋巴结≤2.0 cm且主动监测至少6个月的分化型甲状腺癌患者,排除侵袭性组织学类型及邻近或侵犯局部结构的病灶,共分析40例。

主要发现

  • 40例中女性77.5%,甲状腺乳头状癌97.5%,平均年龄47.0(标准差15.8)岁。
  • TNM第8版分期:I期29例(74.4%),II期8例(20.5%),IV期2例(5.0%)。
  • 淋巴结最大径中位数0.9(四分位距0.8-1.3)cm,主动监测随访中位时间27.5(四分位距16.5-47.3)个月。
  • 疾病进展14例(35%):7例(17.5%)因任一径线增大≥3 mm,7例(17.5%)出现新颈部转移;颈部无进展生存期51.0(置信区间47.0-55.0)个月。
  • 未发现与疾病进展相关的人口学、肿瘤学或生化因素;14例进展者中8例转手术,无永久手术并发症;继续主动监测的6例中5例后续随访(范围6-40个月)无进一步进展。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 回顾性设计。
  • 样本量小。
  • 随访时间短。
  • 需进一步前瞻性及长期研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: The most frequent site of recurrence of differentiated thyroid cancer (DTC) is cervical lymph nodes (LNs), which often necessitates repeated surgical interventions and morbidity in a generally indolent disease. Data on active surveillance (AS) of small cervical nodal metastasis are still scarce, particularly in real-world clinical settings. In this study, we evaluated the DTC outcomes of AS of metastatic cervical LNs and explored factors associated with disease progression. Methods: We conducted a retrospective cohort study, including DTC patients with biopsy-proven metastatic cervical LNs, who were followed on AS in a tertiary care, university-based institution in Brazil. The inclusion criteria were cervical metastasis ≤2.0 cm and an AS duration of at least 6 months. We excluded lesions with aggressive histology, those in close proximity to or invading local structures. The primary outcome was disease progression (enlargement ≥3 mm in any diameter or a new cervical metastasis). Results: Data from 40 patients were analyzed. Most were female (77.5%) and had papillary thyroid cancer (97.5%). The mean age was 47.0 (± standard deviation 15.8) years. The 8th edition of the tumor, node, metastasis stage (TNM8) staging for DTC was as follows: 29 in stage I (74.4%), 8 in stage II (20.5%), and 2 in stage IV (5.0%). The median maximum LN diameter was 0.9 (interquartile range [IQR], 0.8-1.3) cm, and the median AS follow-up duration was 27.5 (IQR, 16.5-47.3) months. Disease progression occurred in 14 (35%) patients: 7 (17.5%) due to enlargement ≥3 mm, and 7 (17.5%) had new cervical metastasis. The cervical progression-free survival was 51.0 (confidence interval, 47.0-55.0) months. No demographic, oncological, or biochemical factors were associated with disease progression. Of the 14 patients with disease progression, 8 were referred for surgery. No permanent surgical complications were reported. Of the six patients who remained on AS despite disease progression, five showed no further progression during subsequent follow-up (range 6-40 months). Conclusions: We observed that most small metastatic cervical LNs remained stable and were safely managed with AS. Nevertheless, these observations are limited by the retrospective design, small sample size, and short follow-up. Further prospective and long-term studies are warranted.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Walter LB, Scheffel RS, Zanella AB, et al. Active Surveillance of Differentiated Thyroid Cancer Metastatic Cervical Lymph Nodes: A Retrospective Single-Center Cohort Study. Thyroid. 2023. PMID: 36680747. doi:10.1089/thy.2022.0542

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。